which was specific of GAD-alum treated patients (16/25 vs. 1/25 in placebo). Assessment of suppressive function in expanded regulatory T cells revealed no difference between GAD-alum and placebo treated individuals. Regulatory T cell frequency did not correlate with C-peptide secretion throughout the study. In conclusion, GAD-alum treatment induced both GAD 65 -reactive CD25 + CD127
Introduction
Type 1 diabetes (T1D) is a consequence of an autoimmune reaction toward insulin producing β-cells of the pancreas. Immunomodulatory approaches to prevent or treat T1D have been developed and tested with variable results [1] [2] [3] [4] . Autoantigens may be used to induce immunologic tolerance as an alternative to immunosuppression [5] . Glutamic Acid Decarboxylase 65 (GAD 65 ) is one of the main antigens to which patients with T1D mount a destructive immune response, and autoantibodies directed against GAD 65 (GADA) and T cells specific for GAD 65 epitopes are common in T1D patients [6] [7] [8] . We have previously shown preservation of residual insulin secretion by GAD-alum treatment in a phase II clinical trial in children with recent-onset T1D [3] . In addition, trial participants treated with GAD-alum up-regulated CD4 + CD25
hi FOXP3 + cells in response to GAD 65 stimulation in vitro and had a predominant T helper (Th) 2 immune response [9] [10] . Preservation of C-peptide secretion was still detectable after 4 years in patients with <6 months T1D duration at baseline in the same trial [11] , and the residual C-peptide secretion was accompanied by sustained high levels of GADA, increased memory T cell frequencies and T cell activation upon in vitro GAD 65 stimulation [12] . Recently, additional phase II and III clinical trials of GAD-alum have been conducted both in Europe and the United States, neither finding an effect on preservation of insulin secretion [13] [14] . The present phase II trial included patients with a T1D duration of <18 months, whereas the European phase III trial included patients with a duration of <3 months, which may contribute to the discrepancy in outcome.
Self tolerance is physiologically maintained by regulatory T cells (Treg) in the periphery [15] , and defects in Treg function have been hypothesized to be involved in the pathogenesis of autoimmune disease [16] . Since tolerance in the periphery is maintained by Tregs, induction of active tolerance has long been a proposed mechanism of action of antigen-based therapies like GAD-alum treatment [17] . Tregs typically express high levels of the interleukin (IL)-2 receptor α-chain CD25, the transcription factor FOXP3 and low levels of the IL-7 receptor CD127 [18] [19] [20] [21] [22] . However, both FOXP3
and CD25 can also be expressed by activated non-regulatory T cells. CD39 has also been suggested to be involved in Treg function through the removal of ATP and has thus been used to identify subsets of Tregs [23] . Tregs can suppress proliferation and cytokine secretion in a broad range of cell types including CD4 + and CD8 + T cells, and their dysfunction leads to immunopathology [24] . It has recently been reported that rather than there being a deficiency in Treg numbers, effector T cells (Teff) from patients with T1D are resistant to Treg-mediated suppression [25] [26] .
The aim of this work was to investigate whether an increase in cells with a Treg phenotype persisted at 4 years after GAD-alum treatment. In addition, we tested whether GAD-alum treatment affected the suppressive capacity of Tregs.
Materials and Methods

Ethics Statement
This study was approved by the Research Ethics Committee at the Faculty of Health Sciences, Linköping University, Sweden. Written informed consent was obtained from participating individuals, and for those <18 years old also their parents, in accordance with the Declaration of Helsinki.
Population
The design and characteristics of the phase II trial have been described elsewhere [3] . Briefly, 70 T1D children between 10 and 18 years of age with less than 18 months of disease duration were recruited at 8 Swedish pediatric centers. Participants had a fasting serum C-peptide level above 0.1 nmol/l and detectable GADA at inclusion. They were randomized to subcutaneous injections of 20 µg GAD-alum (n=35) or placebo (n=35) at day 0 and a booster injection 4 weeks later in a double blind setting.
After 4 years, patients and their parents were asked whether they were willing to participate in a follow-up study. Fifty-nine patients, of whom 29 had been treated with GAD-alum and 30 received placebo, agreed to participate.
Antibodies
Fluorescein isothiocyanate (FITC)-conjugated anti-CD39 (clone A1; Biolegend), phycoerythrin (PE)-
and FITC-and PE-cyanine 7 (PE-Cy7)-conjugated anti-CD127 (clone eBioRDR5; eBioscience), Alexa 700-and Pacific Blue-conjugated anti-CD4 (clone RPA-T4), APC-Cy7-conjugated anti-CD25 (clone M-A251; BD Pharmingen), and relevant isotype-and fluorochrome-matched control antibodies were used in this study. In addition, 7-Amino-Actinomycin D (7-AAD; BD Pharmingen) was used to measure cell viability.
Flow cytometry
Peripheral blood mononuclear cells (PBMC) from GAD-alum treated (n=24) and placebo treated (n=25) patients were isolated from whole blood by Ficoll-Paque (Pharmacia Biotech) density gradient centrifugation within 24 h after drawing. Three of the GAD-alum treated patients were classified as responders, 14 as intermediate responders and 7 were non-responders, while the placebo group contained 10 intermediate responders and 14 non-responders (one patient unclassified due to missing serum sample). PBMC were incubated in AIM-V medium (Invitrogen) with β-mercaptoethanol at 37 °C, 5% CO 2 for 7 days, with or without 5 µg/ml recombinant GAD 65 (Diamyd Medical). One million cells were washed in 2ml Phosphate Buffered Saline (PBS) containing 0.1% bovine serum albumin (BSA; Sigma-Aldrich) and subsequently stained with anti-CD4, CD39, CD127
and CD25 antibodies. Cells were then fixed and permeabilized using a FOXP3 staining kit (eBioscience), according to the manufacturer's instructions. After washing, cells were stained with PE anti-FOXP3, reconstituted in PBS, acquired on a fluorescence activated cell sorter (BD FACSAria) and analyzed using Kaluza software version 1.1 (Beckman Coulter). The FOXP3 + gate was set using the negative population, since the negative population had a higher MFI than the isotype control.
Cell sorting
Cells were sorted and expanded when sufficient cell numbers were available. Cryopreserved cells from GAD-alum-(n=4) and placebo (n=3) treated patients were stained with Pacific Blue conjugated Serum (HS) and allowed to rest for 2 h at 37°C, 5% CO 2 before expansion was initiated. Aliquots of sorted cells were re-acquired to assess purity. The average Teff contaminant in sorted Tregs was 0.1%. PBMC from one single freshly drawn healthy donor were stained, sorted as above and stored frozen to serve as inter-assay control.
Teff and Treg expansion
Tregs were distributed at 4x10 4 cells per well in 125µl AIM-V 10% HS into 96-well U-bottom plates, and stimulated with anti-CD3/CD28 Dynabeads (Invitrogen) at a 1:1 bead-to-cell ratio. Teffs were plated at 5x10 5 cells per 500µl medium, into 96-well flat-bottom plates pre-coated over night with 10µg/ml anti-CD3 (OKT3, eBioscience) at 4°C. Cultures also contained 1µg/ml soluble anti-CD28 antibody (CD28.2, eBioscience). Culture volume was doubled the following day, and 30 and 300 U/ml of recombinant human IL-2 (R&D) were added to Teff and Treg cultures respectively. Tregs were washed and supplemented with fresh IL-2 every two days. Tregs and Teffs were re-stimulated as above on the ninth day of culture, and frozen down after 15 days of expansion. To verify postexpansion phenotype, cryopreserved Tregs and Teffs were cultured for 24h in AIM-V 10% HS and 5U/ml IL-2, and subsequently stained and acquired as described above.
Suppression assay
Treg mediated suppression was assessed using expanded Tregs and Teffs from placebo-(n=3) and GAD-alum (n=4) treated patients. Expanded Tregs and Teffs were thawed and incubated in AIM-V 10% HS at 37°C, 5% CO 2 over night, then re-suspended at 0. 
C-peptide measurements
C-peptide levels were measured in serum samples with a time-resolved fluoroimmunoassay (AutoDELFIA TM C-peptide kit, Wallac), as described [3] . Stimulated C-peptide was measured during a mixed meal tolerance test (MMTT) in GAD-alum (n=21) and placebo (n=10) treated patients who had a maximal C-peptide response of >0.20 nmol/l at the 30-month follow-up. Clinical effect of treatment was defined by changes in stimulated C-peptide measured as area under the curve (AUC) from baseline to 48 months.
Statistical analysis
Statistically significant differences were determined using Mann-Whitney two-tailed U test for unpaired observations, since data was determined to be significantly different from a Gaussian Gates used for analysis and representative PBMC samples describing the expression of CD4, CD25
and CD127 are shown in Figure 1A -B.
The frequency of CD25 hi CD127 lo cells in the CD4 + population was significantly increased upon GAD 65 stimulation in GAD-alum treated patients compared to unstimulated cells (7.4% and 4.5%, respectively), but not in the placebo group ( Figure 1C ). The frequency of CD4 + CD25 + CD127 + cells was also increased following GAD 65 stimulation in the GAD-alum treated patients compared to resting cells (13.1% and 2.6%, respectively; Figure 1D ). In contrast, GAD 65 Figure 2D ). Thus, in vitro GAD recall leads to expansion of both Tregs and activated CD25 + CD127 + T effector cells, which is only observed in patients previously treated with GAD-alum. There were no significant differences in expression of any measured marker on resting cells between the two treatment arms (Figure 1-2) . 
Expression of Treg markers is not related to clinical outcome.
We tested whether the expression of any of the markers affected by GAD 65 stimulation was related to clinical outcome of treatment. We found no significant correlation between expression of Treg markers used in this study and changes in stimulated C-peptide measured as ΔAUC or AUC 4 years after treatment. C-peptide secretion was not significantly different in patients where an FSC hi SSC hi population was induced by GAD 65 stimulation compared to those who did not respond in this way (data not shown).
Suppression of polyclonally activated Teffs is not affected by GAD-alum treatment.
To test whether the function of Tregs in T1D children included in the Phase II trial was affected by GAD-alum or placebo administration, suppression assays using sorted and expanded Tregs Figure 3D ).
Discussion
Previous findings from the phase II GAD-alum trial indicated an ability of GAD-alum to upregulate CD25 and FOXP3 following in vitro stimulation with GAD 65 , in addition to increased secretion of several pro-and anti-inflammatory cytokines from PBMC [9] [10] . Preservation of C-peptide secretion was still present in a 4-year follow-up to the phase II trial [11] , and induction of a T cell subset with memory phenotype was observed upon GAD 65 stimulation [12] .
Here we demonstrate that a great majority of lymphocytes in this T cell subset with memory phenotype expressed FOXP3 and high levels of CD25. Although some differences in the experimental setup were introduced in the present study, the main difference being that PBMC were cultured for 72 h at 21 and 30 months and for 7 days at the 4 year follow-up, the increased frequencies of CD25 hi and FOXP3 + cells detected in this 4 years follow-up of the study are in agreement with our previous findings at 21 and 30 months after treatment [9] . In the present study, the CD127 and CD39 markers were included to further define Tregs. Expression of CD39, an ectonucleotidase expressed on a subset of Tregs which hydrolyzes ATP into AMP [23, 29] , was also increased upon antigen recall in GAD-alum treated patients. It has been postulated that removal of proinflammatory ATP could be a suppressive mechanism mediated by CD39 on Tregs. In a recent study, CD39 + but not CD39 -CD4 + CD25 hi cells were able to suppress IL-17 production [30] . Since the levels of IL-17 were undetectable in the supernatants of both expanded
Teffs and Teff/Treg cultures, we cannot make any conclusion on the ability of Tregs to suppress production of this cytokine in our settings. However we have previously shown that secretion of IL-17, along with that of several other cytokines, was increased by GAD 65 stimulation in PBMC supernatants [12] . Though the current study does not include healthy subjects, the expression of CD39 on resting CD4+CD25 hi CD127 lo cells detected by us in these T1D patients seems to be lower than what has been reported in healthy individuals by others using the same anti-CD39 clone and fluorochrome [30] .
In line with previous findings [31] , expanded CD25 + CD127 lo Tregs were suppressive and retained their phenotype after expansion and cryopreservation. Though we were able to sort, expand and assess suppression in a limited number of individuals, there was no readily evident difference in the suppressive capacity of Tregs between placebo and GAD-alum treated patients 4 years after administration of the treatment. Cross-over culture experiments revealed that Tregs isolated from patients with T1D participating in the GAD-alum trial had an impaired suppressive effect on Though we have identified a deficient Treg-mediated suppression of polyclonal T cell stimulation in T1D patients who participated in the GAD-alum Phase II trial, treatment with GAD-alum did not affect the suppressive activity of Tregs. It should be kept in mind that samples included in the current study have been drawn four years after treatment, and that an effect on suppression shortly after treatment cannot be excluded. Furthermore, due to the random selection of patients based on availability of samples, none of the GAD-alum treated patients classified as responders to treatment were included in suppression assays [10] , and we were thus unable to relate suppression to clinical outcome. Since our assay measures suppression of polyclonal activation, an effect on the specific suppression in response to GAD 65 stimulation cannot be excluded. In fact, changes in the frequency of T cells with a Treg phenotype during the trial have only been observed upon GAD 65 stimulation [9] , while the frequency of Tregs after culture in medium alone has been similar in GAD-alum and placebo treated patients throughout the study. Proliferative responses of PBMC from GAD-alum treated patients in response to GAD 65 stimulation were significantly stronger compared to placebo in a thymidine incorporation assay, as we have previously reported [12] , suggesting that the GAD 65 -specific responses initiated by in vitro antigen recall are not anergic.
In for the persistent clinical benefit of GAD-alum treatment after 4 years [11] .
Figure 1
Gating strategy and GAD 65 -induced T cell populations.
A and B illustrates gating strategy and representative PBMC samples from a GAD-alum treated subject at resting conditions and after in vitro GAD 65 Tables   Table 1 Characteristics of expanded cells after freeze/thaw. 
